A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care

International Clinical Psychopharmacology

Volumn 18, Issue 3, 2003, Pages 133-141

  Wade, Alan ^a,b   Crawford, Gordon M ^a   Angus, Margaret ^a   Wilson, Richard ^a   Hamilton, Lorna ^a  

^a Community Pharmacology Services Ltd ^*  (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Continuation treatment; Double blind randomized study; Major depression; Mirtazapine; Paroxetine; Primary care

Indexed keywords

MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AGITATION; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAPHORESIS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; PAIN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT PLANNING; VERTIGO; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HEADACHE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; NAUSEA; PAROXETINE; PRIMARY HEALTH CARE; SEVERITY OF ILLNESS INDEX; SWEATING; TREATMENT OUTCOME;

EID: 0038064263     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200305000-00002     Document Type: Article

References (27)

1. Åberg-Wistedt A, Ågren H, Ekselius L, Bengtson F, Åkerblad, A-C (2000). Sertraline versus paroxetine in major depression: Clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 20:645-652.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association Press.
3. Bech P (2001). Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. J Int Neuropsychopharmacol 4:337-345.
4. Benkert O, Szegedi A, Kohnen R (2000). Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61:656-663.
5. Brody DS, Hahn SR, Spitzer RL, Kroenke K, Linzer M, deGruy FV III, Williams JB (1998). Identifying patients with depression in the primary care: a more efficient method. Arch Intern Med 158:2469-2475.
6. Demyttenaere K, Mesters P, Boulanger B, Dewe W, Delsemme M-H, Gregoire J, Van Ganse E (2001a). Adherence to treatment regimen in depressed patients treated with amitriptyline and fluoxetine. J Affect Disord 65: 243-252.
7. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, de Bie J, De Troyer W, Mesters P (2001b). Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 62 (suppl 22):30-33.
8. Ellis BW, Johns MW, Lancaster R, Raptopulos P, Angelopulos N, Priest RG (1981). The St Mary's Hospital sleep questionnaire: A study of reliability. Sleep 4:93-97.
9. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC (2000). Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 61:863-867.
10. Gerber PD, Barrett JE, Barrett JA, Oxman E, Manheimer E, Smith R, Whiting RD (1992). The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Med 7:170-173.
11. Guy W (1976). ECDU Assessment Manual for Psychopharmacology, rev. edn. US Department of Health, Education and Welfare. Publication No. (ADM) 76-338. Rockville, MD: National Institutes of Mental Health; pp. 218-222.
12. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Hicks JA, Argyropulos SV, Rich AS, Nash J, Bell CJ, Edwards C, et al. (2002). Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 180:528-535.
14. Huitfeldt B, Montgomery SA (1983). Comparison between zimelidine and amitriptyline of efficacy and adverse symptoms: a combined analysis of four British trials in depression. Acta Psychiatr Scand 68 (suppl 308):55-69.
15. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, et al. (2001). Similar effectiveness of paroxetine, fluoxetine and sertraline in primary care: A randomised trial. JAMA 286:2947-2955.
16. Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997). Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12:19-29.
17. McGahuey MA, Gelenberg A, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R (2000). The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26:25-40.
18. Radhakishun FS, van den Bos J, van der Heijden BC, Roes KC, O'Hanlon JF (2000). Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 20:531-537.
19. Sartorius N (2001). The economic and social burden of depression. J Clin Psychiatry 61 (suppl 15):8-12.
20. Schatzberg A, Kremer C, Rodrigues HE, DeBattista C, Murphy Jr GM, for the Mirtazapine versus Paroxetine Study group (2002). Mirtazapine versus paroxetine in elderly patients. Am J Geriatr Psychiatry 10:541-550.
21. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J (2002). Effects of mirtazapine on sleep polygraphic variables in major depression. Poster presented at the 23rd Collegium Internationale Neuro-Psychopharmacologium (CINP) congress; 23-27 June; Montreal, Canada.
22. Simon GE, VonKorff M, Wagner EH, Barlow W (1993). Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 15:399-408.
23. Thase ME (2000.) Relapse and recurrence in depression: an updated practical approach for prevention. In: Palmer KJ (editor): Drug Treatment Issues in Depression. Auckland, New Zealand: Adis International Ltd; pp. 35-52.
24. Thase ME (2001). Methodology to measure onset of action. J Clin Psychiatry 61 (suppl 15):18-22.
25. Thompson C (2002). Onset of action of antidepressants: Results of different analyses. Hum Psychopharmacol 17 (suppl 1):S27-S33.
26. Wade A, Michael Lemming O, Bang Hedegaard K (2002). Escitalopram 10mg/ day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17:95-102.
27. World Health Organization (1998,) Adverse reactions terminology (WHO-ART). Geneva: World Health Organization.